From: The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management
Study | Patients | Duration | Drugs | Number | MACE | HHF | CV death | Nonfatal MI | Strokea |
---|---|---|---|---|---|---|---|---|---|
CREDENCE [70] | Patients with T2DM and albuminuric CKD | 2.62Â years | Canagliflozin | 2202 | 12.4 | 4.0 | 5.0 | Â | Â |
Placebo | 2199 | 16.4 | 6.4 | 6.4 | Â | Â | |||
P value |  |  | < 0.001 | 0.05 |  |  | |||
EMPA-REG OUTCOME [69] | T2DM patients | 3.1Â years | Empagliflozin | 4687 | 10.5 | 2.7 | 3.7 | 4.5 | 3.2 |
Placebo | 2333 | 12.1 | 4.1 | 5.9 | 5.2 | 2.6 | |||
P value |  | < 0.001 | 0.002 | < 0.001 | 0.22 | 0.16 | |||
EMPEROR-Reduced [68] | Patients with HF and an EF of 40% or less | 16Â months | Empagliflozin | 1863 | 19.4 | 13.2 | 10.0 | Â | Â |
Placebo | 1867 | 24.7 | 18.3 | 10.8 | Â | Â | |||
P value |  | < 0.001 |  |  |  |  | |||
DECLARE–TIMI 58 [13] | T2DM patients and/or atherosclerotic CV disease | 4.2 years | Dapagliflozin | 8582 | 8.8 | 2.5 | 2.9 | 4.6b | 2.7 |
Placebo | 8578 | 9.4 | 3.3 | 2.9 | 5.1b | 2.7 | |||
P value | Â | 0.17 | Â | Â | Â | Â | |||
DAPA-HF [79] | Patients with HF and an EF of 40% or less | 18.2Â months | Dapagliflozin | 2373 | 16.3 | 9.7 | 9.6 | Â | Â |
Placebo | 2371 | 21.2 | 13.4 | 11.5 | Â | Â | |||
P value |  | < 0.001 |  |  |  |  | |||
DAPA-CKD [122] | Patients with Chronic Kidney Disease | 2.4Â years | Dapagliflozin | 2152 | 4.6 | Â | 3.0 | Â | Â |
Placebo | 2152 | 6.4 | Â | 3.7 | Â | Â | |||
P value | Â | 0.009 | Â | Â | Â | Â | |||
VERTIS CV [11] | T2DM patients with atherosclerotic CV disease | 3.5Â years | Ertugliflozin | 5499 | 11.9 | 2.5 | 6.2 | 5.6 | 2.9 |
 | Placebo | 2747 | 11.9 | 3.6 | 6.7 | 5.4 | 2.8 | ||
 | P value |  | < 0.001 |  |  |  |  | ||
CANVAS Programc [50] | T2DM patients with high CV risk | Â | Canagliflozin | 5795 | 26.9 | 5.5 | 11.6 | 9.7 | 7.1 |
 | Placebo | 4347 | 31.5 | 8.7 | 12.8 | 11.6 | 8.4 | ||
 | P valued |  | 0.5980 | 0.2359 | 0.9387 | 0.9777 | 0.4978 |